Printer Friendly

ANERGEN AND NOVO NORDISK ENTER INTO MULTIPRODUCT COLLABORATION

 COPENHAGEN, Denmark, REDWOOD CITY, Calif., and NEW YORK, Aug. 23 /PRNewswire/ -- Anergen Inc. (NASDAQ: ANRG) and Denmark-based pharmaceutical and bioindustrial company Novo Nordisk A/S (NYSE: NVO) today announced the signing of a multifaceted research and development collaboration and an equity investment.
 Under the research and development agreement, Novo Nordisk receives worldwide marketing rights to products developed through the collaboration for Type I diabetes, multiple sclerosis (MS) and myasthenia gravis (MG). Anergen retains North American co-promotion rights for MS and MG.
 Novo Nordisk will fund research and development programs in these therapeutic areas and will provide payments to Anergen upon completion of certain milestones. Both companies will contribute to manufacturing processes and upon product commercialization, Anergen will receive royalty payments from Novo Nordisk based on product sales. Also, under this agreement, a close research and development collaboration is being established between Anergen and ZymoGenetics, a wholly owned subsidiary of Novo Nordisk based in Seattle.
 Under the equity agreement, Novo Nordisk will make an initial $8.0 million equity investment for 1,220,000 shares of common stock representing approximately 17.5 percent of Anergen's outstanding common stock. Harry Penner Jr., president of Novo Nordisk of North America Inc., will join Anergen's board of directors under terms of the agreement.
 The combination of these two agreements could provide up to approximately $25 million for the Anergen projects in addition to future royalties if all milestones are achieved.
 "Anergen is pleased to enter into a collaboration with a company of the stature of Novo Nordisk, the world's leader in the supply of recombinant DNA products. Our companies share the vision that antigen specific therapy offers an exciting opportunity to attack autoimmune diseases and ultimately provide physicians with powerful weapons to use on behalf of their patients," noted John Fara, Ph.D., Anergen's president and chief executive officer. "Novo Nordisk's funding provides us with the opportunity to develop potential therapeutic agents beyond our initial autoimmune programs in MS, MG and rheumatoid arthritis into insulin dependent diabetes, another important autoimmune disease," Fara concluded.
 Erik Sorensen, president of Novo Nordisk's Health Care Group, said, "As world leaders in the development and supply of insulin, we have been treating diabetes for 70 years. Our collaboration with Anergen will improve our understanding of the etiology of diabetes and of other autoimmune diseases, and give us new leads on how to treat these diseases for which there is currently no cure. The technological fit of Anergen and Novo Nordisk will provide a strong basis for further development of products for MS and MG."
 Anergen is developing therapies for the treatment of autoimmune diseases using proprietary biopharmaceutical compounds designed to inactivate or "anergize" only the disease-related T-cells in the immune system that are responsible for each disease.
 Novo Nordisk A/S is a major force in insulin production and diabetes care and is the world's largest producer of industrial enzymes. The company also manufactures and markets a variety of other pharmaceutical and bioindustrial products. Headquartered in Denmark, Novo Nordisk employs more than 11,200 people in 47 countries and markets its products in 130 countries. Its B shares are listed on the stock exchanges in Copenhagen, London, Basle, Zurich and Geneva. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO."
 -0- 8/23/93
 /CONTACT: John Fara, Ph.D., president and CEO, or Joan Shields, investor relations, of Anergen, 4l5-36l-890l; Margaret Jo Ringsted, Novo Nordisk of North America, Corporate Communications, Mogens Vang Rasmussen, Investor Relations, 212-867-0123; Mark Brand or Kimberly Kraemer of Pondel Parsons & Wilkinson, 3l0-207-9300, for Anergen; or Len Ellis of Fleishman Hillard, 212-265-9150/
 (ANRG NVO)


CO: Anergen Inc.; Novo Nordisk A/S; Novo Nordisk of North America Inc. ST: California, Washington IN: MTC SU: JVN

JL-LM -- LA006 -- 4934 08/23/93 09:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:632
Previous Article:MALIBU COMICS UNVEILS 'STAR TREK: DEEP SPACE NINE' COMIC BOOK SERIES WITH LARGEST-EVER PRINTING OF ANY 'STAR TREK(R)' COMIC BOOK TITLE
Next Article:AVALON ENGINEERING, INC., ANNOUNCES PRESENTERPAD FOR APPLE'S NEWTON MESSAGEPAD
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters